What was approved and why it matters
Eli Lilly's Foundayo (orforglipron) is a once daily GLP-1 pill with no food or water restrictions. As a small molecule rather than a peptide, it is easier to manufacture at scale. It launched in the US in the second quarter of 2026, three months after Novo Nordisk's Wegovy pill.
Frequently asked questions
When was Foundayo approved?
The FDA approved Foundayo (orforglipron) for chronic weight management on 1 April 2026. The EU's CHMP gave a positive opinion for obesity and type 2 diabetes on 16 October 2026.
What are Foundayo's projected sales?
Zaash Labs' base case is about USD 12 billion of US net revenue in 2031, within a range of USD 7 billion to 18 billion, depending mainly on how many patients stay on therapy and on net price.
How does Foundayo compare with the Wegovy pill?
Both are once daily oral GLP-1 therapies with similar self pay prices. The Wegovy pill launched first, on 5 January 2026, and passed 5 million US prescriptions by August; Foundayo's advantage is dosing at any time without food or water rules.
Figures are company reported or from published sources unless marked as Zaash Labs estimates. Sources are listed in the executive summary and the full report. Market research to support business decisions; not investment advice.